绿脓杆菌制剂辅助治疗肝癌临床观察(附54例)

A clinic study on PA-MSHA vaccine adjuvant therapy for primary liver cancer(PLC)

目的:观察绿脓杆菌制剂(PA-MSHA)辅助肝动脉化疗栓塞术(TACE术)治疗原发性肝癌的有效性和安全性。方法:采用非盲法随机对照试验。观察组肝癌患者29例,对照组25例。两组均采用相同的TACE术,观察组加用绿脓杆菌制剂。治疗结束后评价疗效和生活质量状况,观察并记录不良反应。结果:观察组有效率(完全缓解+部分缓解)为58.6%,对照组40.0%(P<0.01);观察组生活质量状况改善或稳定者79.3%(23/29),对照组76.0%(19/25);观察组中8例(27.6%)患者出现与绿脓杆菌制剂相关的不良反应,均可缓解。结论:绿脓杆菌制剂联合TACE术治疗肝癌,可提高疗效,且无明显不良反应。

Objective：To evaluate the effectiveness and safety of pseudomonas aeruginous MSHA （PA- MSHA） vaccine used as an adjuvant therapy for PLC with TACE. Methods： We conducted a non - blinded, randomized, controlled trial. 54 patients with PLC were randomly assigned to receive either TACE（ control group, n = 29 ）or the same therapy pins PA -MSHA vaccine（ experimental group, n = 25 ）. The response rate, life quality and adverse reaction were evaluated. Results： The response rate（CR ＋ PR）was 58.6% in the experimental group and 36.0% in the control group（P 〈0.01 ）. Improvement and stabilization of Life quality were found in 79.3% of experimental group and 76.0% of control group（P 〉0.05）. Some adverse events occurred in 8 patients on PA - MSHA vaccine but relieved spontaneously. Conclusion： PA - MSHA vaccine can evidently enhance the effectiveness and safety for PLC therapy adjuvant with TECA.